Illumina: Jay Flatley

Jan 15, 2020

Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.

Breaking News

De Novo Mutation Rate in Humans Higher Than Assumed, Multigenerational Genomics Study Suggests
Watchmaker Genomics, Revvity Partner to Automate Next-Gen Sequencing Workflows
Tempus Signs $200M Deal With AstraZeneca, Pathos AI to Develop Multimodal Cancer Foundation Model
Thermo Fisher Scientific Reports Flat Q1 Revenues, Beating Expectations
ABL Diagnostics to Commercialize Institut Pasteur RNA Seq-Based HPV Test

Illumina: Jay Flatley

De Novo Mutation Rate in Humans Higher Than Assumed, Multigenerational Genomics Study Suggests

Watchmaker Genomics, Revvity Partner to Automate Next-Gen Sequencing Workflows

Tempus Signs $200M Deal With AstraZeneca, Pathos AI to Develop Multimodal Cancer Foundation Model

Thermo Fisher Scientific Reports Flat Q1 Revenues, Beating Expectations

ABL Diagnostics to Commercialize Institut Pasteur RNA Seq-Based HPV Test